Form 4: Kiromic Biopharma Director Michael Catlin Receives Restricted Stock Award
SEC Form 4 Filing
Director Michael Catlin of Kiromic Biopharma, Inc. reports the acquisition of 18,000 shares of restricted stock.
Summary
- Michael Catlin, a director at Kiromic Biopharma, Inc., filed a Form 4 on March 20, 2024.
- The report details a transaction on March 18, 2024, where Catlin acquired 18,000 shares of restricted stock.
- Following the transaction, Catlin beneficially owns 25,500 shares of Kiromic Biopharma, Inc.
- The restricted stock award vests on the one-year anniversary of the grant date.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing detailing a stock award, indicating a neutral sentiment.
Industry Context
This filing is a routine disclosure related to insider transactions and is typical for publicly traded companies. It provides transparency into the holdings of company directors.
Stakeholder Impact
- The granting of restricted stock aligns the director's interests with those of the shareholders.
Key Dates
| Date | Description |
|---|---|
| 03/18/2024 | Date of transaction: Michael Catlin acquired 18,000 shares of restricted stock. |
| 03/20/2024 | Date of Form 4 filing. |
Keywords
Kiromic Biopharma, Michael Catlin, restricted stock, Form 4, beneficial ownership, director
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.